Find recruiting clinical trials for RA in the UK — from early-stage DMARDs to advanced biologic and targeted therapies. See where trials fit into your treatment pathway.
Free to use · Live data from ClinicalTrials.gov · Updated daily
See where clinical trials fit into your treatment journey
Initial treatment after RA diagnosis — typically methotrexate-based
Standard: Methotrexate, Hydroxychloroquine, Sulfasalazine, or Leflunomide
When conventional DMARDs fail to achieve remission or low disease activity
Standard: TNF inhibitors (Adalimumab, Etanercept), Abatacept, Rituximab, or Tocilizumab
After biologic failure or intolerance — oral targeted therapies
Standard: Tofacitinib, Baricitinib, Upadacitinib, or Filgotinib
Persistent disease activity despite multiple therapies — trials are especially important
Standard: Clinical trial, combination biologic strategies, or novel mechanisms
An autoimmune condition causing chronic joint inflammation. Affects about 400,000 people in the UK. Can cause joint damage, pain, fatigue, and reduced mobility if not treated early and aggressively.
Despite many approved treatments, up to 30% of RA patients don't respond adequately. New therapies targeting different pathways (B cells, T cells, JAK-STAT, IL-6) are constantly being studied.
Modern RA care aims for remission or low disease activity. If your current treatment isn't achieving this, a clinical trial may offer access to next-generation therapies before they're widely available.
Loading trials from ClinicalTrials.gov...